Two myeloid leukemia cases with rare FLT3 fusions.
Two myeloid leukemia cases with rare FLT3 fusions.
复制标题
两例罕见 FLT3 融合的骨髓性白血病病例。
DOI：
10.1101/mcs.a003079
复制
发表时间：
2018
影响因子：
1.8
通讯作者：
Tyner,JeffreyW
中科院分区：
文献类型：
--
作者：
Zhang,Haijiao;Paliga,Aleksandra;Hobbs,Evie;Moore,Stephen;Olson,Susan;Long,Nicola;Dao,Kim-HienT;Tyner,JeffreyW
涉及FLT 3的基因重排很少见，最近才在嗜酸性粒细胞增多相关的骨髓/淋巴肿瘤（MLN-eos）和慢性骨髓增生性疾病中检测到。在这里，我们报告两例FLT 3融合的患者表现出骨髓增生异常/骨髓增生性肿瘤的混合特征。在第一个病例中，FLT 3与一个新的融合伴侣MYO 18 A融合，该患者的骨髓特征与非典型慢性髓细胞白血病最一致;第二个病例涉及ETV 6-FLT 3融合，该病例的骨髓特征与慢性粒单核细胞白血病最一致。值得注意的是，我们观察到来自两名患者的样品在离体药物筛选测定中表现出FLT 3抑制剂（quizartinib和索拉非尼）敏感性。
Genetic rearrangements involvingFLT3are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases withFLT3fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case,FLT3was fused with a new fusion partnerMYO18Ain a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involvingETV6-FLT3fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.